spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  Primary Immunodeficiency 

 HSMN NewsFeed - 27 Feb 2026
Norgine Welcomes Positive CHMP Opinion Recommending Approval of Mavorixafor in the European Union for WHIM Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 2 Oct 2024
Kedrion and Biotest complete long-term Exclusive Distribution Agreement for Yimmugo(R) in the US
Biopharmaceuticals Distribution
 HSMN NewsFeed - 9 Dec 2019
HIZENTRA(R) (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 21 Feb 2019
Enzyvant Appoints Industry Veteran Rachelle Jacques as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jul 2018
Enzyvant Expands Leadership Team with Appointments of Andrew Dawson and Alex Tracy
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Mar 2018
FDA Approves Hizentra(R) (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Feb 2015
FDA Approves New Dosing Option for CSL Behring's Hizentra(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 May 2014
Baxter Provides U.S. Regulatory Update on HyQvia, Its Investigational Subcutaneous Treatment for Primary Immunodeficiency
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Sep 2013
CSL Behring Announces FDA Approval of a 10 g (50 mL) Vial Size for Hizentra(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Oct 2012
Study Supports Efficacy, Safety of Hizentra(R) in Japanese Patients with Primary Immunodeficiency Disease
Biopharmaceuticals
 HSMN NewsFeed - 27 Jun 2012
PRIMA Study Shows Treatment with Privigen(R) Improved Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Biopharmaceuticals
 HSMN NewsFeed - 25 Jun 2012
Baxter Announces FDA Approval for GAMMAGARD LIQUID as a Treatment for Multifocal Motor Neuropathy
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 25 Jul 2011
Baxter Announces FDA Approval of Subcutaneous Route of Administration for GAMMAGARD LIQUID for Patients with Primary Immunodeficiency
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Oct 2010
Talecris Biotherapeutics Receives FDA Approval for Gamunex(R)-C
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Oct 2010
Data Support Hizentra(R) Efficacy, Safety After Dose-Equivalent Switch in Adult and Pediatric Patients with Primary Immunodeficiency
Biopharmaceuticals
 HSMN NewsFeed - 7 Oct 2010
Study Demonstrates Safety and Efficacy of Subcutaneous Vivaglobin(R) as First-Line Therapy for Primary Immunodeficiency
Biopharmaceuticals
 HSMN NewsFeed - 13 Apr 2010
Baxter and New York-Presbyterian/Weill Cornell Announce 18-Month Data from Phase II Study of GAMMAGARD in Patients with Alzheimer's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Dec 2009
FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus
Diagnostics FDA
 HSMN NewsFeed - 15 Jul 2009
Baxter and Halozyme Announce Completion of Patient Enrollment in Phase III Pivotal Trial of GAMMAGARD LIQUID with rHuPH20 Enzyme
Biopharmaceuticals
 HSMN NewsFeed - 16 Mar 2009
Data Presented at AAAAI Reinforce Baxter's Commitment to Making GAMMAGARD LIQUID Therapy More Convenient
Biopharmaceuticals
 HSMN NewsFeed - 6 Jan 2009
Kawasaki Disease Treated with Plasma-Derived Therapy
Biopharmaceuticals
 HSMN NewsFeed - 10 Sep 2007
Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 28 Aug 2007
Baxter and The Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimer's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 Aug 2007
Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 10

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 10 additional stories matching:
Primary Immunodeficiency
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!